Cevostamab, CAS 2249888-53-5

Product Description: Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Li J, et al. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing. Cancer Cell. 2017 Mar 13;31(3):383-395. /[2]Hosny M, et al. Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. J Clin Med. 2021 Oct 6;10(19):4593.

CAS Number: 2249888-53-5

Molecular Weight: N/A

Compound Purity: 95.00

Research Area: Cancer; Neurological Disease

Solubility: 10 mM in DMSO

Target: CD3

• Artikelnummer: MEXHY-P99601-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99601-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated